Mitochondria are pleomorphic organelles [1, 2] that have central roles in cell physiology. Defects in their localization and dynamics lead to human disease [3] [4] [5] . Myosins are actin-based motors that power processes such as muscle contraction, cytokinesis, and organelle transport [6] . Here we report the initial characterization of myosin-XIX (Myo19), the founding member of a novel class of myosin that associates with mitochondria. The 970 aa heavy chain consists of a motor domain, three IQ motifs, and a short tail. Myo19 mRNA is expressed in multiple tissues, and antibodies to human Myo19 detect an w109 kDa band in multiple cell lines. Both endogenous Myo19 and GFP-Myo19 exhibit striking localization to mitochondria. Deletion analysis reveals that the Myo19 tail is necessary and sufficient for mitochondrial localization. Expressing full-length GFP-Myo19 in A549 cells reveals a remarkable gain of function where the majority of the mitochondria move continuously. Moving mitochondria travel for many micrometers with an obvious leading end and distorted shape. The motility and shape change are sensitive to latrunculin B, indicating that both are actin dependent. Expressing the GFP-Myo19 tail in CAD cells resulted in decreased mitochondrial run lengths in neurites. These results suggest that this novel myosin functions as an actin-based motor for mitochondrial movement in vertebrate cells.
Results and Discussion

Myo19 Encodes a Novel Metazoan Myosin
Previous sequence analysis predicted an uncharacterized myosin gene on human chromosome 17q12 that appeared to represent a novel myosin class [7, 8] . With the database sequence FLJ22865 (myohd1, GI: 14286205), we generated polymerase chain reaction (PCR) primers to clone the fulllength coding region of this putative myosin from human pancreas cDNA. Sequence analysis of the PCR-amplified clone revealed a 970 aa coding region consisting of a myosin motor domain, a neck region containing three IQ motifs, and a short tail ( Figure 1A ). The Myo19 motor domain shares w35% sequence identity with the motor domains of human skeletal muscle myosin, Myo5a, and Myo6. The motor contains the conserved GESGAGKT sequence from the P loop, DXXGFE sequence from switch-2 (DVYGFE), and a slightly divergent MEAFGNACTLRNNNSSRFGK in the switch-1 region (see Figure S1A available online; reviewed in [9] ). Myo19 has a glutamine at the TEDS position, indicating that it is not regulated by heavy-chain phosphorylation at this site [10] . The three IQ motifs in the neck region are expected to bind calmodulin or calmodulin-like light chains [11] . The 146 aa tail domain is basic (pI w 9.2) and is not predicted to form a coiled coil [12] . Interestingly, the tail has no obvious sequence homology with other proteins in the databases, except for other Myo19 orthologs ( Figure S1B ). FLJ22865 corresponds to a 770 aa Myo19 sequence lacking four sequential exons from the core motor domain and is thus likely to represent either an aberrant cDNA or a splice form with a nonfunctional motor. Clear orthologs of human Myo19 are present in multiple vertebrate species including mouse (GI: 56206893), chicken (GI: 118100337), Xenopus laevis (GI: 62185680), and zebrafish (GI: 189519181). At the amino acid level, human Myo19 (970 aa) exhibits 82% identity to mouse Myo19 (963 aa) and 56% identity to Xenopus laevis Myo19 (971 aa). Although Myo19 arose early in metazoan evolution, it appears to have been lost from lineages leading to Drosophila and C. elegans [8] .
Myo19 Is Expressed in Multiple Tissues and Cell Lines
To determine the tissue expression pattern of Myo19, we probed a northern blot with a sequence from the 3 0 noncoding region. A band of approximately 4.2 kb was detected in multiple tissues ( Figure 1B) . Analysis of expressed sequence tag (EST) databases (Table S1 ) and the Allen Brain Atlas (http://www.brain-map.org) indicate that Myo19 is broadly expressed in vertebrate cells, tissues, and tumors. Antibodies raised against the Myo19 peptide AKELDGVEEKHFS (aa 829-841) detected a protein of the expected size of w109 kDa in western blots of human and other primate cell lines ( Figure 1C ). We also detected Myo19 in mouse cell lines (B16-F1 and CAD), but the signal was weaker, likely because of sequence differences in the antibody target (SKELDGMEEKPMP in mouse).
Myo19 Localizes to Mitochondria
To determine the cellular localization of Myo19, we immunostained multiple cell lines (A549, HeLa, and COS-7) with antiMyo19 antibody. Colocalization with MitoTracker-stained mitochondria revealed clear and striking localization of endogenous Myo19 to mitochondria (Figure 2A ; Figure S2A ). To determine the region of Myo19 required for mitochondrial localization, we generated a series of GFP constructs containing different regions of the Myo19 protein. Full-length GFP-Myo19 and a ''tail'' construct containing amino acids 801-970 both clearly localized to mitochondria ( Figure 2B ; Figure S2B ). However, a construct containing the motor domain and IQ motifs (aa 1-828) did not localize to mitochondria and exhibited diffuse cytoplasmic staining with some *Correspondence: oaq100@psu.edu brighter puncta ( Figure 2B ; Figure S2B ). To test whether Myo19 is anchored to the mitochondrial outer membrane via insertion of a C-terminal transmembrane helix [13] , we added GFP to the C terminus [14] . Expression of either a Myo19 tail or a full-length Myo19 construct GFP-tagged at the C terminus resulted in mitochondrial localization. Taken together, these data indicate that the tail domain of Myo19 is necessary and sufficient for mitochondrial localization via a mechanism that is unlikely to involve a C-terminal transmembrane helix (Figure 2C) .
To test whether Myo19 is stably associated with mitochondria, we used fluorescence recovery after photobleaching (FRAP) analysis (Movie S1). GFP-Myo19 tail displayed recovery dynamics similar to those of cytochrome b 5 (GFPCytob5-RR), a transmembrane protein that localizes to the outer mitochondrial membrane [15] (Figure S3 ). Six minutes following the bleaching event, neither construct recovered its fluorescence completely (52% 6 7% recovery GFP-Myo19 tail, n = 16; 53% 6 4% GFP-cytob5-RR, n = 10), and both constructs had a time to 50% maximum recovery (t 1/2 ) of greater than 2 min ( Figure S3B ). The lack of fluorescence recovery cannot be accounted for by simple photofading due to visualization of the samples, because unbleached regions of the same or neighboring cells did not lose significant amounts of fluorescence over the same time period. Although the Myo19 tail shares no obvious sequence homology with class I myosin tails, both Myo19 and class I myosin tail regions contain a large number of basic residues. In class I myosins, these basic residues mediate the binding to specific phospholipids in the membrane [16] . Although it is possible that binding to acidic phospholipids may anchor Myo19 to mitochondria, it is unlikely that the Myo19 and Myo1 mechanisms are identical, because the FRAP dynamics of Myo1A are much faster (w80% recovery in less than 1 min) than those of Myo19 [17] . These data indicate that Myo19 does not rapidly exchange and suggest that it is tightly associated with the mitochondrial outer membrane.
Expressing GFP-Myo19 Alters Mitochondrial Dynamics
To test whether Myo19 functions in actin-based mitochondrial motility, we transfected A549 cells with GFP-Myo19, pDsRed2-Mito (as a control), or both plasmids in combination and then used time-lapse imaging to assess mitochondrial dynamics. In control A549 cells, the vast majority of mitochondria remained largely in place with only small ''jostling'' movements (Movie S2). Expressing GFP-Myo19, however, led to a dramatic increase in mitochondrial motility (Movie S3; Figure 3A) . In approximately 40% of the cells expressing GFP-Myo19, the majority of mitochondria moved continuously for many micrometers with one end of the mitochondrion leading. The leading end was often wider than the trailing end, resulting in a tadpole-like appearance ( Figure 3B ; Movie S3). Unlike microtubule-dependent movements, these mitochondrial movements were neither linear nor obviously directed to or from the cell center ( Figure 3A ; Movie S4).
To quantify the increase in mitochondrial motility induced by GFP-Myo19, we determined a ''displacement index'' (DI) by dividing the area over which the mitochondrial network moved in a 3:20 (min:s) time lapse by the area occupied by mitochondria in the first frame of the recording ( Figure S4 ). If the mitochondrial network remained perfectly stationary, then DI = 1. Control A549 cells had a DI of 1.2 6 0.1 (n = 10 cells), whereas the DI in GFP-Myo19 cells increased by 75% to 2.1 6 0.7 (n = 28 cells, p < 0.0003; Figure S4D ). Additionally, the values for DI from cells expressing GFP-Myo19 alone were not statistically different from the DI values calculated from cells expressing both pDsRed2-Mito and GFP-Myo19 (2.2 6 0.16, n = 19 cells). These data demonstrate that expression of GFP-Myo19 dramatically increases mitochondrial dynamics.
As an additional measure of mitochondrial motility, we also calculated the average velocities of randomly selected mitochondria in control A549 cells and A549 cells transfected with GFP-Myo19. The velocities of control mitochondria formed a broad peak centered at relatively low velocities, whereas the velocity distribution for GFP-Myo19 mitochondria was shifted to the right and had an additional small peak in the 50-75 nm/s range ( Figure 3C ). The average velocity of randomly selected mitochondria in the control cells was 16 6 1 nm/s (n = 121 mitochondria, 12 cells). Expressing GFP-Myo19 resulted in an average velocity of 29 6 2 nm/s (n = 153 mitochondria, 8 cells; p < 0.0001), an 80% increase over control cells. Expression of GFP-Myo19 in conjunction with pDsRed2-Mito also resulted in a similar increase in velocity over control cells (31 6 2 nm/s, n = 62 mitochondria, 8 cells; p < 0.0001) and was not significantly different from cells expressing GFP-Myo19 alone. Because these measurements included mitochondria from all GFP-Myo19 cells, including those that exhibited little movement, the average velocity in the w40% of A549 cells that exhibited increased mitochondrial movement would be even greater. When velocities were measured by selecting for mitochondria that were exhibiting long-range, end-on movements, the mitochondria in GFPMyo19 cells that were moving continuously had an average velocity of 73 6 3 nm/s (n = 125 mitochondria, 8 cells). In control cells, the average of moving mitochondria was 102 6 7 nm/s (n = 27 mitochondria, 6 cells). These values are similar to the value of the additional minor peak in the histograms of velocities for randomly chosen mitochondria.
GFP-Myo19-Induced Mitochondrial Motility Is Actin Dependent and Requires the Myo19 Motor Domain
We hypothesize that the movements of mitochondria we observed are powered by interactions between the Myo19 motor domain and randomly organized actin filaments. To test whether the observed gain of function requires the Myo19 motor domain, we measured the DI ( Figure S4C mitochondrial motility, indicating that the motor domain of Myo19 is required for enhanced mitochondrial dynamics. To test whether these movements are indeed actin based, cells expressing full-length GFP-Myo19 were treated with 15 mM nocodazole to disrupt microtubules or 500 nM latrunculin B to disrupt F-actin. This dose of nocodazole was sufficient to disrupt the distribution of the endoplasmic reticulum within 5 min (data not shown). Mitochondrial movements induced by GFP-Myo19 were insensitive to nocodazole treatments (Figure 4A ; Movies S5-S7). These mitochondria continued to display movement over many micrometers, and the tadpole shape remained. However, upon addition of latrunculin B to nocodazole-treated cells, the end-on, directed movements ceased ( Figure 4B ; Movies S5-S7). In addition, the mitochondria lost their asymmetric shape within 2 min of latrunculin B treatment ( Figure 4C) . Treatment of cells with latrunculin B without nocodazole pretreatment also resulted in a prompt cessation of end-on mitochondrial movement and a rapid loss of the asymmetric shape, demonstrating that both the motility and altered shape are dependent on the presence of F-actin (Movie S9).
An alternative to the hypothesis that the motor activity of Myo19 powers mitochondria movements would be that Myo19 recruits F-actin to the mitochondria and actin polymerization pushes the organelle via a mechanism similar to Listeria motility [18] [19] [20] . However, mitochondria in GFP-Myo19-expressing cells did not exhibit phase-dense tails similar to those reported for Listeria ( Figure 3B ; Movies S4 and S6). To determine whether GFP-Myo19-labeled mitochondria lack actin tails, we coexpressed the nonperturbing F-actin label mRFP-utrophin [21] in combination with full-length GFPMyo19. Although we observed mRFP-utrophin labeling of other F-actin structures such as filopodia, we did not observe F-actin tails behind GFP-Myo19-labeled mitochondria (Figure S5A ; Movies S11 and S12). Additionally, we took time-lapse movies of GFP-Myo19-expressing cells on gridded coverslips, allowing us to locate cells with increased mitochondrial dynamics prior to fixation and phalloidin staining. Again, the mitochondria lacked Listeria-like actin tails ( Figure S5B ; Movie S13). When GFP-utrophin-expressing A549 cells were infected with fluorescent Listeria, actin clouds and actin tails associated with the bacteria ( Figure S5C ; Movie S14). Taken together, these data indicate that Myo19-induced movement is unlikely to be due to polymerization-mediated pushing.
Although the lack of directed mitochondrial movement in control A549 cells was ideal for gain-of-function experiments, it was problematic for loss-of-function studies. Because expression of myosin tails has been widely used as a dominant-negative approach to investigate the functions of unconventional myosins [22] [23] [24] and previous work has shown that mitochondrial motility in neurites is partially actin based [25] [26] [27] , we expressed the Myo19 tail in CAD cells [28] to test the function of Myo19 in normal mitochondrial dynamics. In CAD cell neurites, where mean run lengths can be measured relatively easily, expressing GFP-Myo19 tail resulted in a 40% decrease in mitochondrial run length from 1.4 6 0.3 mm (n = 141) for control cell (pDsRed2-Mito-labeled) mitochondria to 0.8 6 0.1 mm (n = 250) for GFP-Myo19 tail-labeled mitochondria ( Figure 4D , p < 0.03). This suggests that Myo19 function is indeed necessary for normal mitochondrial dynamics.
Myo19 Is a Novel Mitochondrial-Associated Myosin that Is
Likely to Function in Actin-Based Mitochondrial Dynamics Taken together, our data strongly suggest that Myo19 is a broadly expressed mitochondrial myosin involved in actinmediated mitochondrial movements and positioning. Endogenous Myo19 localizes to mitochondria, and the FRAP and truncation analyses indicate that Myo19 localizes to mitochondria via its tail domain. Expression of full-length GFP-Myo19 protein induces a dramatic increase in mitochondrial motility in A549 cells, and we observed similar increases in mitochondrial motility in COS-7 and B16-F1 cells (data not shown). As predicted for myosin-driven movements, these movements require the motor domain, because GFP-Myo19 tail expression did not result in the enhancement of mitochondrial dynamics observed in cells expressing full-length GFPMyo19. Additionally, these movements are indeed actin based, because GFP-Myo19-induced movements cease upon destabilization of the actin network. Because the striking increase in mitochondrial motility was not observed in 100% of the cells expressing GFP-Myo19, it is likely that additional factors regulate Myo19 function and/or mitochondrial movement. Whether those conditions are related to the amount of Myo19 on the mitochondrial surface or to the activation state of Myo19 motor has yet to be determined. Expression of the GFP-Myo19 tail may impact the activity level of Myo19 on the mitochondrial surface by displacing endogenous, functional Myo19. In CAD cell neurites, expression of GFP-Myo19 tail resulted in a 40% decrease in mitochondrial run lengths, lending further support to the hypothesis that Myo19 is involved in mitochondrial dynamics. The localization and dynamics of mitochondria are critical to their function, and disruption of these processes leads to human disease [29, 30] . Mitochondrial localization and dynamics have been shown to involve both microtubules and actin [31] [32] [33] [34] [35] . However, the mechanism of actin-based mitochondrial movements in vertebrates remains unclear [36] . Our discovery of a novel class of myosin that localizes to mitochondria provides a possible molecular mechanism for actin-based mitochondrial movements.
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